Previous 10 | Next 10 |
2023-11-04 11:45:28 ET Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Results Conference Call November 01, 2023 09:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - President and CEO Eric Hyllengren - CFO Co...
Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.63 for Q3 2023
2023-11-01 17:51:54 ET More on Atara Biotherapeutics Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis Readout Mizuho values Atara's US tab-cel deal at $450M, or $4/share Atara licenses out US Tab-cel rights, plans to cut 30% of workforc...
2023-11-01 12:48:58 ET More on Atara Biotherapeutics Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis Readout Atara licenses out US Tab-cel rights, plans to cut 30% of workforce Atara sees filing for FDA approval of Tab-cel in Q2 2024 ...
2023-11-01 11:11:03 ET More on Atara Biotherapeutics Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis Readout Atara sees filing for FDA approval of Tab-cel in Q2 2024 Seeking Alpha’s Quant Rating on Atara Biotherapeutics ...
Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel ® , including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tier...
2023-09-20 10:00:02 ET More on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutive week Wolfe Research stays defensive as it says markets wi...
2023-09-20 08:29:58 ET Exscientia ( EXAI ) +30% climbs as Merck KGaA joins AI drug discovery. Regulus Therapeutics ( RGLS ) +16% Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose Clinical Trial o...
2023-09-19 18:18:44 ET More on Atara Biotherapeutics Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeutics Financial information for Atara Biotherapeutics Atara Biotherapeutics: A Speculative Buy On Up...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulator...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...